Nivolumab + BMS-986205 for Endometrial Cancer

Recruiting in Palo Alto (17 mi)

+9 other locations

Overseen byChrisann Kyi, MD

Age: 18+

Sex: Female

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Memorial Sloan Kettering Cancer Center

No Placebo Group

Prior Safety Data

Breakthrough Therapy

Approved in 4 Jurisdictions

Trial Summary

What is the purpose of this trial?This study will compare the effects of treatment with nivolumab alone versus those of nivolumab plus the experimental drug BMS-986205. Adding BMS-986208 to nivolumab could shrink the cancer or prevent it from returning, but it could also cause side effects.

Eligibility Criteria

This trial is for women over 18 with certain types of persistent or recurrent endometrial cancer, including carcinosarcoma. They must have had one prior platinum-based chemotherapy and can't be pregnant or breastfeeding. Participants need measurable disease by specific criteria, adequate organ function, and a life expectancy of at least 12 weeks.

Inclusion Criteria

I have had one platinum-based chemotherapy for endometrial cancer.

I am fully active or can carry out light work.

My condition is recurrent or persistent endometrial cancer or carcinosarcoma.

+21 more

Exclusion Criteria

I experience seizures that my medication cannot control.

History of hypersensitivity to nivolumab

You have received an organ transplant from another person in the past.

+27 more

Participant Groups

The study compares the effects of nivolumab alone to nivolumab combined with an experimental drug called BMS-986205 in treating endometrial cancer that hasn't responded to previous treatments. The goal is to see if adding BMS-986205 improves outcomes.

2Treatment groups

Experimental Treatment

Group I: Nivolumab with IDO-inhibitor, BMS- 986205Experimental Treatment2 Interventions

Nivolumab 480 mg every 4 weeks with BMS-986205 100 mg.

Group II: Nivolumab aloneExperimental Treatment1 Intervention

Nivolumab 480 mg every 4 weeks.

Nivolumab is already approved in United States, European Union, Canada, Switzerland for the following indications:

🇺🇸 Approved in United States as Opdivo for: